APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hyperimmune Globulins

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Selected research

Market Structure

Global Hyperimmune Globulins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025195 pages

Choose your research edition.

Industry ResearchHyperimmune Globulins Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hyperimmune Globulins Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Hyperimmune Globulins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hyperimmune Globulins Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Hyperimmune Globulins Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.

Read the full market overview

Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.

In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

This report provides an overview of the global Hyperimmune Globulins market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hyperimmune Globulins and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hyperimmune Globulins sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hyperimmune Globulins market size, projected growth trends, production technologies, key applications, and end-use industries.

Hyperimmune Globulins Segment by Company

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Hyperimmune Globulins Segment by Type

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Other

Hyperimmune Globulins Segment by Application

Government Institutions

Private Sector

Other

Hyperimmune Globulins Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Globulins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Globulins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Globulins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hyperimmune Globulins market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hyperimmune Globulins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hyperimmune Globulins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hyperimmune Globulins Industry Trends Table 2. Hyperimmune Globulins Industry Drivers Table 3. Hyperimmune Globulins Industry Opportunities and Challenges Table 4. Hyperimmune Globulins Industry Restraints Table 5. Global Hyperimmune Globulins Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hyperimmune Globulins Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hyperimmune Globulins Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Hyperimmune Globulins Sales Market Share by Manufacturers Table 9. Global Hyperimmune Globulins Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Hyperimmune Globulins Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hyperimmune Globulins Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hyperimmune Globulins Manufacturers, Product Type & Application Table 13. Global Hyperimmune Globulins Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hyperimmune Globulins by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Hepatitis B Immunoglobulins Table 17. Major Manufacturers of Rabies Immunoglobulins Table 18. Major Manufacturers of Tetanus Immunoglobulins Table 19. Major Manufacturers of Rho(D) Immunoglobulins Table 20. Major Manufacturers of Other Table 21. Global Hyperimmune Globulins Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Hyperimmune Globulins Sales by Type (2021-2026) & (K Units) Table 23. Global Hyperimmune Globulins Sales by Type (2027-2032) & (K Units) Table 24. Global Hyperimmune Globulins Sales Market Share by Type (2021-2026) Table 25. Global Hyperimmune Globulins Sales Market Share by Type (2027-2032) Table 26. Global Hyperimmune Globulins Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Hyperimmune Globulins Revenue by Type (2021-2026) & (K Units) Table 28. Global Hyperimmune Globulins Revenue by Type (2027-2032) & (K Units) Table 29. Global Hyperimmune Globulins Revenue Market Share by Type (2021-2026) Table 30. Global Hyperimmune Globulins Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Government Institutions Table 32. Major Manufacturers of Private Sector Table 33. Major Manufacturers of Other Table 34. Global Hyperimmune Globulins Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Hyperimmune Globulins Sales by Application (2021-2026) & (K Units) Table 36. Global Hyperimmune Globulins Sales by Application (2027-2032) & (K Units) Table 37. Global Hyperimmune Globulins Sales Market Share by Application (2021-2026) Table 38. Global Hyperimmune Globulins Sales Market Share by Application (2027-2032) Table 39. Global Hyperimmune Globulins Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Hyperimmune Globulins Revenue by Application (2021-2026) & (K Units) Table 41. Global Hyperimmune Globulins Revenue by Application (2027-2032) & (K Units) Table 42. Global Hyperimmune Globulins Revenue Market Share by Application (2021-2026) Table 43. Global Hyperimmune Globulins Revenue Market Share by Application (2027-2032) Table 44. Global Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Hyperimmune Globulins Sales by Region (2021-2026) & (K Units) Table 46. Global Hyperimmune Globulins Sales Market Share by Region (2021-2026) Table 47. Global Hyperimmune Globulins Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Hyperimmune Globulins Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 51. North America Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 52. Europe Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 54. Europe Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 61. Global Hyperimmune Globulins Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Hyperimmune Globulins Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Hyperimmune Globulins Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Hyperimmune Globulins Revenue Market Share by Region (2021-2026) Table 65. Global Hyperimmune Globulins Revenue Market Share by Region (2027-2032) Table 66. CSL Behring Company Information Table 67. CSL Behring Business Overview Table 68. CSL Behring Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. CSL Behring Hyperimmune Globulins Product Portfolio Table 70. CSL Behring Recent Development Table 71. Grifols Company Information Table 72. Grifols Business Overview Table 73. Grifols Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Grifols Hyperimmune Globulins Product Portfolio Table 75. Grifols Recent Development Table 76. Biotest Company Information Table 77. Biotest Business Overview Table 78. Biotest Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biotest Hyperimmune Globulins Product Portfolio Table 80. Biotest Recent Development Table 81. Kedrion Company Information Table 82. Kedrion Business Overview Table 83. Kedrion Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Kedrion Hyperimmune Globulins Product Portfolio Table 85. Kedrion Recent Development Table 86. CBPO Company Information Table 87. CBPO Business Overview Table 88. CBPO Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. CBPO Hyperimmune Globulins Product Portfolio Table 90. CBPO Recent Development Table 91. Emergent (Cangene) Company Information Table 92. Emergent (Cangene) Business Overview Table 93. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Emergent (Cangene) Hyperimmune Globulins Product Portfolio Table 95. Emergent (Cangene) Recent Development Table 96. Kamada Company Information Table 97. Kamada Business Overview Table 98. Kamada Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Kamada Hyperimmune Globulins Product Portfolio Table 100. Kamada Recent Development Table 101. CNBG Company Information Table 102. CNBG Business Overview Table 103. CNBG Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. CNBG Hyperimmune Globulins Product Portfolio Table 105. CNBG Recent Development Table 106. Hualan Bio Company Information Table 107. Hualan Bio Business Overview Table 108. Hualan Bio Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Hualan Bio Hyperimmune Globulins Product Portfolio Table 110. Hualan Bio Recent Development Table 111. Shanghai RAAS Company Information Table 112. Shanghai RAAS Business Overview Table 113. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Shanghai RAAS Hyperimmune Globulins Product Portfolio Table 115. Shanghai RAAS Recent Development Table 116. Sichuan Yuanda Shuyang Company Information Table 117. Sichuan Yuanda Shuyang Business Overview Table 118. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio Table 120. Sichuan Yuanda Shuyang Recent Development Table 121. ADMA Biologics Company Information Table 122. ADMA Biologics Business Overview Table 123. ADMA Biologics Hyperimmune Globulins Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. ADMA Biologics Hyperimmune Globulins Product Portfolio Table 125. ADMA Biologics Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Hyperimmune Globulins Distributors List Table 129. Hyperimmune Globulins Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Hyperimmune Globulins Product Image Figure 2. Global Hyperimmune Globulins Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hyperimmune Globulins Market Size (2021-2032) & (US$ Million) Figure 4. Global Hyperimmune Globulins Sales (2021-2032) & (K Units) Figure 5. Global Hyperimmune Globulins Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hyperimmune Globulins Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Hepatitis B Immunoglobulins Image Figure 9. Rabies Immunoglobulins Image Figure 10. Tetanus Immunoglobulins Image Figure 11. Rho(D) Immunoglobulins Image Figure 12. Other Image Figure 13. Global Hyperimmune Globulins Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Hyperimmune Globulins Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Hyperimmune Globulins Sales Market Share by Type (2021-2032) Figure 16. Global Hyperimmune Globulins Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Hyperimmune Globulins Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Hyperimmune Globulins Revenue Market Share by Type (2021-2032) Figure 19. Government Institutions Image Figure 20. Private Sector Image Figure 21. Other Image Figure 22. Global Hyperimmune Globulins Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Hyperimmune Globulins Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Hyperimmune Globulins Sales Market Share by Application (2021-2032) Figure 25. Global Hyperimmune Globulins Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Hyperimmune Globulins Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Hyperimmune Globulins Revenue Market Share by Application (2021-2032) Figure 28. North America Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 30. U.S. Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 35. Germany Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 42. China Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 50. Brazil Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Hyperimmune Globulins Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Hyperimmune Globulins Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Hyperimmune Globulins Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 61. North America Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 63. Europe Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Hyperimmune Globulins Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Hyperimmune Globulins Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Hyperimmune Globulins Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Immunoglobulins
  • Rabies Immunoglobulins
  • Tetanus Immunoglobulins
  • Rho(D) Immunoglobulins
  • Other
Applications
  • Government Institutions
  • Private Sector
  • Other
Companies covered
  • CSL Behring
  • Grifols
  • Biotest
  • Kedrion
  • CBPO
  • Emergent (Cangene)
  • Kamada
  • CNBG
  • Hualan Bio
  • Shanghai RAAS
  • Sichuan Yuanda Shuyang
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hyperimmune Globulins Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hyperimmune Globulins Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hyperimmune Globulins Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hyperimmune Globulins Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hyperimmune Globulins Market Dynamics
  1. 2.1 Hyperimmune Globulins Industry Trends
  2. 2.2 Hyperimmune Globulins Industry Drivers
  3. 2.3 Hyperimmune Globulins Industry Opportunities and Challenges
  4. 2.4 Hyperimmune Globulins Industry Restraints
3 Hyperimmune Globulins Market by Manufacturers
  1. 3.1 Global Hyperimmune Globulins Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hyperimmune Globulins Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hyperimmune Globulins Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hyperimmune Globulins Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hyperimmune Globulins Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hyperimmune Globulins Manufacturers, Product Type & Application
  7. 3.7 Global Hyperimmune Globulins Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hyperimmune Globulins Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hyperimmune Globulins Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hyperimmune Globulins Tier 1, Tier 2, and Tier 3
4 Hyperimmune Globulins Market by Type
  1. 4.1 Hyperimmune Globulins Type Introduction
  2. 4.1.1 Hepatitis B Immunoglobulins
  3. 4.1.2 Rabies Immunoglobulins
  4. 4.1.3 Tetanus Immunoglobulins
  5. 4.1.4 Rho(D) Immunoglobulins
  6. 4.1.5 Other
  7. 4.2 Global Hyperimmune Globulins Sales by Type
  8. 4.2.1 Global Hyperimmune Globulins Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hyperimmune Globulins Sales by Type (2021-2032)
  10. 4.2.3 Global Hyperimmune Globulins Sales Market Share by Type (2021-2032)
  11. 4.3 Global Hyperimmune Globulins Revenue by Type
  12. 4.3.1 Global Hyperimmune Globulins Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Hyperimmune Globulins Revenue by Type (2021-2032)
  14. 4.3.3 Global Hyperimmune Globulins Revenue Market Share by Type (2021-2032)
5 Hyperimmune Globulins Market by Application
  1. 5.1 Hyperimmune Globulins Application Introduction
  2. 5.1.1 Government Institutions
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Hyperimmune Globulins Sales by Application
  6. 5.2.1 Global Hyperimmune Globulins Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hyperimmune Globulins Sales by Application (2021-2032)
  8. 5.2.3 Global Hyperimmune Globulins Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hyperimmune Globulins Revenue by Application
  10. 5.3.1 Global Hyperimmune Globulins Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hyperimmune Globulins Revenue by Application (2021-2032)
  12. 5.3.3 Global Hyperimmune Globulins Revenue Market Share by Application (2021-2032)
6 Global Hyperimmune Globulins Sales by Region
  1. 6.1 Global Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hyperimmune Globulins Sales by Region (2021-2032)
  3. 6.2.1 Global Hyperimmune Globulins Sales by Region (2021-2026)
  4. 6.2.2 Global Hyperimmune Globulins Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hyperimmune Globulins Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hyperimmune Globulins Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hyperimmune Globulins Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hyperimmune Globulins Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hyperimmune Globulins Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hyperimmune Globulins Revenue by Region
  1. 7.1 Global Hyperimmune Globulins Revenue by Region
  2. 7.1.1 Global Hyperimmune Globulins Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hyperimmune Globulins Revenue by Region (2021-2026)
  4. 7.1.3 Global Hyperimmune Globulins Revenue by Region (2027-2032)
  5. 7.1.4 Global Hyperimmune Globulins Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hyperimmune Globulins Revenue (2021-2032)
  8. 7.2.2 North America Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hyperimmune Globulins Revenue (2021-2032)
  11. 7.3.2 Europe Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hyperimmune Globulins Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hyperimmune Globulins Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hyperimmune Globulins Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Behring
  2. 8.1.1 CSL Behring Company Information
  3. 8.1.2 CSL Behring Business Overview
  4. 8.1.3 CSL Behring Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSL Behring Hyperimmune Globulins Product Portfolio
  6. 8.1.5 CSL Behring Recent Developments
  7. 8.2 Grifols
  8. 8.2.1 Grifols Company Information
  9. 8.2.2 Grifols Business Overview
  10. 8.2.3 Grifols Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Grifols Hyperimmune Globulins Product Portfolio
  12. 8.2.5 Grifols Recent Developments
  13. 8.3 Biotest
  14. 8.3.1 Biotest Company Information
  15. 8.3.2 Biotest Business Overview
  16. 8.3.3 Biotest Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biotest Hyperimmune Globulins Product Portfolio
  18. 8.3.5 Biotest Recent Developments
  19. 8.4 Kedrion
  20. 8.4.1 Kedrion Company Information
  21. 8.4.2 Kedrion Business Overview
  22. 8.4.3 Kedrion Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kedrion Hyperimmune Globulins Product Portfolio
  24. 8.4.5 Kedrion Recent Developments
  25. 8.5 CBPO
  26. 8.5.1 CBPO Company Information
  27. 8.5.2 CBPO Business Overview
  28. 8.5.3 CBPO Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CBPO Hyperimmune Globulins Product Portfolio
  30. 8.5.5 CBPO Recent Developments
  31. 8.6 Emergent (Cangene)
  32. 8.6.1 Emergent (Cangene) Company Information
  33. 8.6.2 Emergent (Cangene) Business Overview
  34. 8.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio
  36. 8.6.5 Emergent (Cangene) Recent Developments
  37. 8.7 Kamada
  38. 8.7.1 Kamada Company Information
  39. 8.7.2 Kamada Business Overview
  40. 8.7.3 Kamada Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Kamada Hyperimmune Globulins Product Portfolio
  42. 8.7.5 Kamada Recent Developments
  43. 8.8 CNBG
  44. 8.8.1 CNBG Company Information
  45. 8.8.2 CNBG Business Overview
  46. 8.8.3 CNBG Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CNBG Hyperimmune Globulins Product Portfolio
  48. 8.8.5 CNBG Recent Developments
  49. 8.9 Hualan Bio
  50. 8.9.1 Hualan Bio Company Information
  51. 8.9.2 Hualan Bio Business Overview
  52. 8.9.3 Hualan Bio Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio
  54. 8.9.5 Hualan Bio Recent Developments
  55. 8.10 Shanghai RAAS
  56. 8.10.1 Shanghai RAAS Company Information
  57. 8.10.2 Shanghai RAAS Business Overview
  58. 8.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio
  60. 8.10.5 Shanghai RAAS Recent Developments
  61. 8.11 Sichuan Yuanda Shuyang
  62. 8.11.1 Sichuan Yuanda Shuyang Company Information
  63. 8.11.2 Sichuan Yuanda Shuyang Business Overview
  64. 8.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio
  66. 8.11.5 Sichuan Yuanda Shuyang Recent Developments
  67. 8.12 ADMA Biologics
  68. 8.12.1 ADMA Biologics Company Information
  69. 8.12.2 ADMA Biologics Business Overview
  70. 8.12.3 ADMA Biologics Hyperimmune Globulins Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio
  72. 8.12.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hyperimmune Globulins Value Chain Analysis
  2. 9.1.1 Hyperimmune Globulins Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hyperimmune Globulins Production Mode & Process
  6. 9.2 Hyperimmune Globulins Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hyperimmune Globulins Distributors
  9. 9.2.3 Hyperimmune Globulins Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst